このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

TCP-600 Supplementation and Performance Response in Professional Football Players (TCP600-RESP)

2026年11月1日 更新者:Krzysztof Mizera、Vizja University in Warsaw

Multidimensional Responses to Taurine-Caffeine Supplementation With and Without Phosphatidylserine in Professional Football Players: A 28-Day Randomised, Placebo- and Active-Controlled Trial

This 28-day randomised, placebo- and active-controlled trial investigated multidimensional responses to taurine-caffeine supplementation with or without phosphatidylserine in 65 male professional and highly trained football players.

Participants were allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or the same combination supplemented with phosphatidylserine 600 mg/day (TCP-600). Assessments were conducted before and after the intervention and covered physical performance, cognitive function, cardiac autonomic modulation and football-specific perceptual-cognitive performance.

The primary outcome was the proportion of participants showing favourable responses in at least two of four predefined assessment domains. The principal treatment comparison was TCP-600 versus TC, with comparisons involving placebo providing additional information on the effects of supplementation.

調査の概要

詳細な説明

This randomised, masked, placebo- and active-controlled trial examined physical, cognitive, autonomic and football-specific perceptual-cognitive responses to 28 days of supplementation in professional and highly trained male football players.

Participants were randomly allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or taurine 1500 mg/day plus caffeine 200 mg/day and phosphatidylserine 600 mg/day (TCP-600). Assessments were performed before supplementation and after the intervention.

The primary outcome was the proportion of multidimensional responders, defined as participants meeting favourable-response criteria in at least two of four assessment domains: physical performance, cognitive performance, autonomic/recovery-related response and football-specific perceptual-cognitive performance.

Secondary assessments included 30 m sprint performance, cognitive reaction time, cardiac autonomic modulation assessed using LnRMSSD, readiness to train, perceived fatigue, football-specific decision-making, response time and visual search behaviour. The study also monitored supplementation adherence and adverse events.

The principal treatment comparison was TCP-600 versus TC, allowing assessment of the additional effect of phosphatidylserine within a fixed taurine-caffeine supplementation regimen. Comparisons with placebo were also conducted.

Post-completion clarification (November 2026): The original registration included external validation of a previously developed responder prediction model, with AUROC as a secondary outcome. This analysis was not performed because a previously finalised prediction model suitable for independent validation was unavailable. The analysis therefore focuses on observed multidimensional response and treatment-group comparisons. The omission of the originally registered prediction-model validation analysis is disclosed as a deviation from the initial analysis plan.

研究の種類

介入

入学 (実際)

65

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Krakow、ポーランド
        • Professional Football Training Center
      • Lodz、ポーランド、01-043
        • Professional Football Training Center
      • Warsaw、ポーランド、01-043
        • Professional Football Training Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~37年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

男

説明

Inclusion Criteria:

  • Male professional or highly trained football players aged 18-37 years.
  • Regular participation in structured football training and team activities.
  • Minimum of 5 years of structured football training experience.
  • Regular involvement in club training during the study period.
  • Medical clearance or no known contraindications to high-intensity exercise testing.
  • Ability to complete sprint, reaction-time, cognitive-fatigue, heart-rate-variability, wellness/readiness, and selected football-specific perceptual-cognitive assessments where available.
  • Willingness to maintain usual diet and training habits during the study period.
  • Willingness to avoid additional ergogenic supplements outside the study protocol during the intervention.
  • Willingness to follow caffeine restrictions before testing sessions.
  • Written informed consent provided before participation.

Exclusion Criteria:

  • Current musculoskeletal injury or illness preventing full participation in training or testing.
  • Musculoskeletal injury within the previous 3 months that may affect sprint, football-specific performance, or perceptual-cognitive testing.
  • Cardiovascular, metabolic, neurological, psychiatric, or other chronic disease that may affect safety or study outcomes.
  • Diagnosed sleep disorder.
  • Use of medication affecting heart rate, autonomic nervous system function, sleep, cognition, or exercise performance.
  • Known hypersensitivity or intolerance to caffeine, taurine, phosphatidylserine, or any supplement ingredient.
  • Regular use of ergogenic supplements that cannot be discontinued before and during the study period.
  • Smoking or regular use of nicotine products.
  • Participation in another interventional study during the same period.
  • Inability to comply with supplementation, monitoring, or testing procedures.
  • Failure to provide written informed consent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo

Participants assigned to this arm will receive placebo capsules for 28 consecutive days. Placebo capsules will be matched to the active supplement in appearance, number, packaging, and administration schedule.

Matching placebo capsules administered orally once daily for 28 consecutive days. The placebo was matched to the active supplements in appearance, number, packaging, and administration schedule.

アクティブコンパレータ:Taurine + Caffeine

Participants assigned to this arm will receive taurine 1500 mg/day and anhydrous caffeine 200 mg/day, administered orally once daily for 28 consecutive days. Matching placebo capsules will be used to maintain the same total number and appearance of capsules across study arms.

Taurine 1500 mg/day administered orally once daily in capsules for 28 consecutive days.

Anhydrous caffeine 200 mg/day administered orally once daily in capsules for 28 consecutive days.

実験的:Taurine + Caffeine + Phosphatidylserine

Participants assigned to this arm will receive a multi-ingredient supplementation protocol containing taurine 1500 mg/day, anhydrous caffeine 200 mg/day, and phosphatidylserine 600 mg/day, administered orally once daily for 28 consecutive days. This intervention is referred to as the TCP-600 protocol.

Taurine 1500 mg/day administered orally once daily in capsules for 28 consecutive days.

Anhydrous caffeine 200 mg/day administered orally once daily in capsules for 28 consecutive days.

Phosphatidylserine 600 mg/day administered orally once daily in capsules for 28 consecutive days.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants Classified as Multidimensional Responders After 28 Days
時間枠:Baseline to post-intervention after 28 days of supplementation

Proportion of participants classified as multidimensional responders after 28 days of supplementation. A multidimensional responder will be defined as a participant meeting the predefined response criterion in at least two of four domains: physical performance/fatigue resistance, cognitive fatigue-related performance, recovery/readiness, and football-specific perceptual-cognitive performance. The outcome will be reported as the percentage of participants classified as multidimensional responders in each group.

Unit of Measure: percentage of participants

Baseline to post-intervention after 28 days of supplementation

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in 30 m Sprint Time
時間枠:Baseline to post-intervention after 28 days of supplementation

Change in 30 m sprint performance from baseline to post-intervention testing. Sprint time will be measured using electronic timing gates. Participants will perform three maximal 30 m sprint trials separated by standardized recovery periods, and the best valid trial will be used for analysis.

Baseline to post-intervention after 28 days of supplementation
Change in Cognitive Fatigue Task Reaction Time
時間枠:Baseline to post-intervention after 28 days of supplementation

Change in reaction time during the computerized cognitive fatigue task from baseline to post-intervention testing after 28 days of supplementation. Reaction time will be measured during the predefined cognitive task performed under cognitive load. The outcome will be reported as the mean change in reaction time from baseline to post-intervention testing. Lower values indicate faster cognitive responses.

Unit of Measure: milliseconds

Baseline to post-intervention after 28 days of supplementation
Change in Perceived Mental Fatigue VAS Score
時間枠:Baseline to post-intervention after 28 days of supplementation.

Change in perceived mental fatigue from baseline to post-intervention testing after 28 days of supplementation. Perceived mental fatigue will be assessed using a 0-10 visual analogue scale, where 0 indicates no perceived mental fatigue and 10 indicates maximal perceived mental fatigue. The outcome will be reported as the mean change in score from baseline to post-intervention testing. Higher scores indicate greater perceived mental fatigue.

Unit of Measure:

points on a 0-10 scale

Baseline to post-intervention after 28 days of supplementation.
Change in Final 3-Day Mean LnRMSSD
時間枠:Baseline monitoring period to final 3 days of supplementation.

Change in heart rate variability from baseline monitoring to the final 3 days of supplementation. Heart rate variability will be expressed as the natural logarithm of the root mean square of successive RR interval differences. Morning HRV will be recorded under standardized resting conditions. The outcome will be reported as the mean change in final 3-day mean LnRMSSD compared with the baseline monitoring period.

Unit of Measure: ln(ms)

Baseline monitoring period to final 3 days of supplementation.
Change in Readiness-to-Train Rating Scale Score
時間枠:Baseline monitoring period to final 3 days of supplementation.

Change in self-reported readiness to train from baseline monitoring to the final 3 days of supplementation. Readiness to train will be assessed using a single-item readiness-to-train rating scale scored from 1 to 10, where 1 indicates very poor readiness and 10 indicates excellent readiness. The outcome will be reported as the mean change in readiness-to-train score from the baseline monitoring period to the final 3-day supplementation period. Higher scores indicate greater perceived readiness to train.

Unit of Measure: points on a 1-10 scale

Baseline monitoring period to final 3 days of supplementation.
Change in Hooper and Mackinnon Wellness Questionnaire Fatigue Item Score
時間枠:Baseline monitoring period to final 3 days of supplementation.

Change in self-reported fatigue from baseline monitoring to the final 3 days of supplementation. Fatigue will be assessed using the fatigue item of the Hooper and Mackinnon wellness questionnaire. The item is scored on a 1-7 scale. The outcome will be reported as the mean change in fatigue item score from the baseline monitoring period to the final 3-day supplementation period. Higher scores indicate greater perceived fatigue.

Unit of Measure: points on a 1-7 scale

Baseline monitoring period to final 3 days of supplementation.
Area Under the Receiver Operating Characteristic Curve for the Predefined Responder Model
時間枠:Post-intervention after 28 days of supplementation.

Predictive performance of the predefined responder model in the independent validation cohort will be assessed using the area under the receiver operating characteristic curve. The model will compare predicted responder status with observed multidimensional responder status after 28 days of supplementation. Higher values indicate better discrimination.

Unit of Measure: area under the curve Post-completion clarification (November 2026): The originally planned AUROC analysis was not performed because a previously finalised prediction model was not available for independent validation. No prediction model was developed using the present cohort as a substitute. This deviation from the original analysis plan will be disclosed in the study publication.

Post-intervention after 28 days of supplementation.
Number of Participants With Supplement-Related Adverse Events
時間枠:During the 28-day supplementation period

Number of participants reporting at least one supplement-related adverse event during the 28-day supplementation period. Participants will be asked to report gastrointestinal symptoms, sleep disturbances, headache, palpitations, nervousness, or any other unusual symptoms.

Unit of Measure: participants

During the 28-day supplementation period
Change in Football-Specific Video Decision-Making Task Response Time
時間枠:Baseline to post-intervention after 28 days of supplementation.

Change in response time during the football-specific video decision-making task from baseline to post-intervention testing after 28 days of supplementation. Response time will be measured as the time from presentation of the decision prompt to participant response. The outcome will be reported as the mean change in response time from baseline to post-intervention testing. Lower values indicate faster football-specific decision-making.

Unit of Measure: milliseconds

Baseline to post-intervention after 28 days of supplementation.
Change in Football-Specific Video Decision-Making Task Accuracy
時間枠:Baseline to post-intervention after 28 days of supplementation.

Change in football-specific decision-making accuracy from baseline to post-intervention testing after 28 days of supplementation. Decision-making accuracy will be assessed using a football-specific video decision-making task. Participants will view standardized football-specific scenarios and select the most appropriate tactical decision. The outcome will be reported as the mean change in the percentage of correct decisions from baseline to post-intervention testing. Higher values indicate better football-specific decision-making accuracy.

Unit of Measure: percentage of correct decisions

Baseline to post-intervention after 28 days of supplementation.
Change in Eye-Tracking Time to First Fixation on the Optimal Tactical Option
時間枠:Baseline to post-intervention after 28 days of supplementation.

Change in visual search behavior from baseline to post-intervention testing after 28 days of supplementation. Visual search behavior will be assessed using eye-tracking during the football-specific video decision-making task. Time to first fixation will be defined as the time from scenario onset to the first fixation on the predefined optimal tactical option. The outcome will be reported as the mean change in time to first fixation from baseline to post-intervention testing. Lower values indicate faster visual orientation toward the optimal tactical option.

Unit of Measure: milliseconds

Baseline to post-intervention after 28 days of supplementation.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月7日

一次修了 (実際)

2026年10月8日

研究の完了 (実際)

2026年10月8日

試験登録日

最初に提出

2026年7月4日

QC基準を満たした最初の提出物

2026年7月13日

最初の投稿 (実際)

2026年7月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月1日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared due to participant confidentiality and the small, potentially identifiable nature of the professional athlete sample. Aggregated results may be reported in publications. Selected anonymized analysis outputs may be made available from the corresponding author upon reasonable request, where ethically and legally appropriate.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する